Neoadjuvant nivolumab for resectable lung cancer

Bookmark and Share
Published: 25 Apr 2018
Views: 1123
Rating:
Save
Dr Drew Pardoll - Johns Hopkins Medicine, Baltimore, USA

Dr Pardoll presents at AACR 2018 about outcomes from a trial of 20 patients who received anti-PD1 nivolumab before surgical resection.

Pathological responses were observed in 45% of patients and, at a median follow-up of 12 months, 16 patients remain recurrence free.

For more from Dr Pardoll, watch his interview with ecancer here.